Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Torre LA, Islami F, Siegel RL, et al. Global Cancer in Women: burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–457.
   PubMed Web of Science ®Google Scholar
• Allen JA, Duke JC, Davis KC, et al. Using mass media campaigns to reduce youth tobacco use: a review. Am J Health Promot. 2015;30(2):e71–82.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Martinez P, Peters S, Stammers T, et al. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2019 Jan 14. doi: 10.1158/1078-0432.CCR-18-3904.
   Google Scholar
• Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):pii: 120858.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019; 37 (7): 537-546.
   Web of Science ®Google Scholar
• Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov. 2013;12(10):743–755.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies–the key to unlocking precision medicine. N Engl J Med. 2016;375(1):4–6.
   PubMed Web of Science ®Google Scholar
• Ocana A, Ethier JL, Díez-González L, et al. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015;6(37):39538–39549.
   PubMed Web of Science ®Google Scholar
• Roscoe DM, Hu YF, Philip R. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Rev Mol Diagn. 2015;15(7):869–880.
   PubMed Web of Science ®Google Scholar
• Jørgensen JT, Hersom M. Companion diagnostics-a tool to improve pharmacotherapy. Ann Transl Med. 2016b;4(24):482.
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. When biomarkers define a drug indication. Expert Rev Mol Diagn. 2018;18(4):315–317.
   PubMed Web of Science ®Google Scholar
• Lee EY, Shen HC. Regulatory considerations for companion diagnostic devices. Biomark Med. 2015;9(1):67–75.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC, Kerr KM Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019 Feb 4. doi: 10.1038/s41571-019-0173-9.
   Google Scholar
• Agarwal A. Do companion diagnostics make economic sense for drug developers? N Biotechnol. 2012;29(6):695–708.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration, In Vitro Diagnostics - Companion Diagnostics, U.S. Dept. of Health & Human Services. 2016. https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm
   Google Scholar
• Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res. 2014;20(6):1453–1457.
   PubMed Web of Science ®Google Scholar
• Pignatti F, Ehmann F, Hemmings R, et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union. Clin Cancer Res. 2014 Mar;20(6):1458–1468.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res. 2014;20(6):1445–1452.
   PubMed Web of Science ®Google Scholar
• Shimazawa R, Ikeda M. International differences in companion diagnostic approvals: how are we able to manage the differences? Expert Rev Mol Diagn. 2015;15(2):157–159.
   PubMed Web of Science ®Google Scholar
• Wurcel V, Perche O, Lesteven D, et al. The value of companion diagnostics: overcoming access barriers to transform personalised health care into an affordable reality in Europe. Public Health Genomics. 2016;19(3):137–143.
   PubMed Web of Science ®Google Scholar
• Jørgensen JT, Nielsen KB. Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. Transl Lung Cancer Res. 2018;7(Suppl 2):S95–S99.
   PubMedGoogle Scholar
• Conde E, Hernandez S, Prieto M, et al. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn. 2016;16(6):707–713.
   PubMed Web of Science ®Google Scholar
• Hendry S, Byrne DJ, Wright GM, et al. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. J Thorac Oncol. 2018;13(3):367–376.
   PubMed Web of Science ®Google Scholar
• Hofman P. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn. 2017;17(12):1097–1108.
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn. 2016a;16(2):131–133.
   PubMed Web of Science ®Google Scholar
• Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–881.
   PubMed Web of Science ®Google Scholar
• Glorikian H, Warburg RJ, Moore K, et al. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics. Expert Opin Ther Pat. 2018;28(2):123–128.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019.
   PubMed Web of Science ®Google Scholar
• Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol. 2015;13(6):e1002165.
   PubMed Web of Science ®Google Scholar
• Cooreman A, Bravo E, van Gool AJ, et al. Point of View: traceability and transparency should be mandatory for all human biospecimens. Appl Clin Trials. 2017. http://www.appliedclinicaltrailsonline.com/print/333964?page=full.
   Google Scholar
• Hofman P, Bréchot C, Zatloukal K, et al. Public-private relationships in biobanking: a still underestimated key component of open innovation. Virchows Arch. 2014;464(1):3–9.
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911–919.
   PubMed Web of Science ®Google Scholar
• Luo D, Smith JA, Meadows NA, et al. A quantitative assessment of factors affecting the technological development and adoption of companion diagnostics. Front Genet. 2016;28(6):357.
   Google Scholar
• Zaric GS. Cost Implications of value-based pricing for companion diagnostic tests in precision medicine. Pharmacoeconomics. 2016;34(7):635–644.
   PubMed Web of Science ®Google Scholar
• http://www.biotechnologyevents.com/node/5753 Accessed 30 November 2014
   Google Scholar
• Herbst RS, Redman MW, Kim ES, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018;19(1):101–114.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Edelman MJ, O’Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2014;32(5 suppl):A#8000.
   Google Scholar
• West H. The failure of figitumumab: the danger of taking shortcuts in drug development. Ann Oncol. 2015;26(3):447–448.
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–991.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Menis J, Reck M. Prospects of targeted and immune therapies in SCLC. Expert Rev Anticancer Ther. 2018 Dec 28:1-17. doi: 10.1080/14737140.2019.1559057.
   Google Scholar
• Lashari BH, Vallatharasu Y, Kolandra L, et al. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate. Drugs R D. 2018;18(4):255–258.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Pourat J, Abdel-Atti D, et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res. 2017;77(14):3931–3941.
   PubMed Web of Science ®Google Scholar
• Peters S, Dafni U, Boyer M, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019. DOI:10.1093/annonc/mdy553.
   Web of Science ®Google Scholar
• Heeke S, Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? Transl Lung Cancer Res. 2018;7(6):631–638.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L. Lung cancer with a high tumor mutational burden. N Engl J Med. 2018;379(11):1093–1094.
   PubMedGoogle Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
   PubMed Web of Science ®Google Scholar
• Buchhalter I, Rempel E, Endris V, et al. Size matters: dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer. 2019;144(4):848–858.
   PubMed Web of Science ®Google Scholar
• Stenzinger A, Allen JD, Maas J, et al. Tumor mutational burden (TMB) standardization initiatives: recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019 Jan 21. doi: 10.1002/gcc.22733.
   Google Scholar
• Odogwu L, Mathieu L, Blumenthal G, et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E Mutations. Oncologist. 2018;23(6):740–745.
   PubMed Web of Science ®Google Scholar
• Sini C, Tuzi A, Rossi G, et al. Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncol. 2018;14(13s):29–40.
   PubMedGoogle Scholar
• Hofman V, Hofman P. Resistances to EGFR tyrosine kinase inhibitors in lung cancer— how to routinely track them in a molecular pathology laboratory? J Thoracic Dis. 2019a.
   Web of Science ®Google Scholar
• Bernabé R, Hickson N, Wallace A, et al. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? Eur J Cancer. 2017;81:66–73.
   PubMed Web of Science ®Google Scholar
• Liang Z, Cheng Y, Chen Y, et al. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIs. Cancer Lett. 2017;403:186–194.
   PubMed Web of Science ®Google Scholar
• Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–215.
   PubMed Web of Science ®Google Scholar
• Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018 Nov;15(11):694–708.
   PubMed Web of Science ®Google Scholar
• Torga G, Pienta KJ. Patient-paired sample congruence between 2 commercial liquid biopsy tests. JAMA Oncol. 2018;4(6):868–870.
   PubMed Web of Science ®Google Scholar
• VanderLaan PA, Rangachari D, Costa DB. Lung cancer with a high tumor mutational burden. N Engl J Med. 2018;379(11):1093.
   PubMedGoogle Scholar
• Bassanelli M, Sioletic S, Martini M, et al. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 2018;38(7):3789–3796.
   PubMed Web of Science ®Google Scholar
• Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–153.
   PubMed Web of Science ®Google Scholar
• Jia Q, Wu W, Wang Y, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018 18;9(1):5361.
   PubMedGoogle Scholar
• Wang L, Zhu B, Zhang M, et al. Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer. Semin Cell Dev Biol. 2017;64:90–97.
   PubMed Web of Science ®Google Scholar
• Wu D, Wang DC, Cheng Y, et al. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Semin Cancer Biol. 2017;42:13–19.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Tzou A, Blumenthal GM, et al. An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin Cancer Res. 2017;23(6):1368–1372.
   PubMed Web of Science ®Google Scholar
• Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326–344.
   PubMed Web of Science ®Google Scholar
• Mao Q, Jiang F, Yin R, et al. Interplay between the lung microbiome and lung cancer. Cancer Lett. 2018;415:40–48.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–285.
   PubMed Web of Science ®Google Scholar
• Vivarelli S, Salemi R, Candido S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel). 2019;11(1):pii: E38.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Daillère R, Roberti MP, et al. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15(8):465–478.
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–4250.
   PubMed Web of Science ®Google Scholar
• O‘Donnell JS, Teng MWL, Smyth MJ Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16(3):151-167.
   Google Scholar
• Weber JS, Yang JC, Atkins MB, et al. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099.
   PubMed Web of Science ®Google Scholar
• Hofman P, Tartour E, Henderson F, et al. Multiplexed immunohistochemistry for molecular and immune profiling in lung cancer – just about ready for prime-time? Cancers (Basel). 2019.
   Google Scholar
• Tolstikov V, Akmaev VR, Sarangarajan R. et al. Clinical metabolomics: a pivotal tool for companion diagnostic development and precision medicine.Expert. Rev Mol Diagn. 2017;17(5):411–413.
   PubMed Web of Science ®Google Scholar
• Hofman P. Radiomic features of the lung: a promising marker to predict response to immune checkpoint inhibitors in non-small lung cancer patients. Precision Cancer Med. 2019;2:3
   Google Scholar
• Mankoff DA, Edmonds CE, Farwell MD, et al. Development of Companion Diagnostics. Semin Nucl Med. 2016;46(1):47–56.
   PubMed Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–1191.
   PubMed Web of Science ®Google Scholar
• Hofman P. The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. J Thoracic Dis. 2019b;11:S57-S64.
   PubMed Web of Science ®Google Scholar
• Rabbani M, Kanevsky J, Kafi K, et al. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. Eur J Clin Invest. 2018;48:4.
   Web of Science ®Google Scholar
• Bussolati G, Annaratone L, Maletta F. The pre-analytical phase in surgical pathology. Recent Results Cancer Res. 2015;199:1–13.
   PubMedGoogle Scholar
• Neumeister VM, Juhl H. Tumor pre-analytics in molecular pathology: impact on protein expression and analysis. Curr Pathobiol Rep. 2018;6(4):265–274.
   PubMedGoogle Scholar
• Brown D, Zingone A, Yu Y, et al. Relationship between circulating inflammation proteins and lung cancer diagnosis in the national lung screening trial. Cancer Epidemiol Biomarkers Prev. 2019;28(1):110–118.
   PubMed Web of Science ®Google Scholar
• Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises and challenges. J Thorac Oncol 2019;14(3):343-357.
   Google Scholar
• http://www.cofrac.fr; (2019).
   Google Scholar
• https://economie.fgov.be/fr/themes/qualite-securite/accreditation (2019).
   Google Scholar
• Frederickson AM, Arndorfer S, Zhang I, et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2019; 11 (5): 407-428.
   Web of Science ®Google Scholar
• Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953–958.
   PubMed Web of Science ®Google Scholar
• Ionescu DN, Downes MR, Christofides A, et al. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr Oncol. 2018;25(3):e209–e216.
   PubMed Web of Science ®Google Scholar
• Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29(10):1165–1172.
   PubMed Web of Science ®Google Scholar